10 Best Biotech Stocks Under $10 to Buy

2. Nuvation Bio Inc. (NYSE:NUVB)

Number of Hedge Fund Holders: 42

Market Capitalization as of October 27: $1.60 Billion

Share Price as of October 27: $4.55

Nuvation Bio Inc. has struggled in 2026, with its shares down more than 45% compared to a 31% gain for biotech stocks in the S&P 500. The big question now is whether it is still one of the best biotech stocks under $10 to buy as it develops its oncology portfolio.

The company’s long-term prospects hinge on its three principal assets. IBTROZI (taletrectinib) is the company’s FDA-approved treatment for non-small cell lung cancer. It is also the most near-term revenue driver. The company is also developing Safusidenib as an investigational IDH1 inhibitor for IDH1-mutant Glioma. What are analysts saying about Ibtrozi commercialization?

Wall Street is optimistic about its long-term prospects. Citi initiated coverage with a Buy rating and a $12 price target on September 30. It touted it as an emerging oncology leader given the commercialization progress, as safusidenib also offers new growth opportunities. Cantor Fitzgerald shares a similar view, having reiterated an Overweight rating and a $12 price target on August 21, as it expects Ibtrozi sales to peak at $965 million.

While Nuvation Bio Inc. remains under pressure, financial results indicate the company is starting to generate meaningful product revenue. Net product revenues attributed to IBTROZI surged 25% quarter over quarter in the second quarter to $23.2 million, affirming continued adoption. Can Nuvation Stock bounce back?

While Nuvation Bio has underperformed in 2026, its declining share price does not undermine its long-term investment case. Commercial progress and safusidenib developments provide a credible foundation for a bullish long-term thesis.